MDxHealth SA MDXH

Company Overview

MDxHealth SA is a molecular diagnostics company focused on precision medicine solutions for urologic cancers, particularly prostate cancer. The company develops and commercializes genomic and epigenetic tests designed to support physicians in cancer detection, risk stratification, treatment selection, and disease monitoring. MDxHealth operates within the molecular diagnostics, oncology diagnostics, and precision health industries, serving healthcare providers, urology practices, hospitals, and laboratory networks primarily in the United States and Europe.

The company’s principal revenue drivers are its proprietary diagnostic assays, including Confirm mdx, Select mdx, GPS (Genomic Prostate Score), and Resolve mdx, which are used to help guide clinical decisions related to prostate cancer diagnosis and treatment planning. MDxHealth evolved through a combination of internal assay development and strategic acquisitions, most notably the acquisition of Genomic Health’s urology business from Exact Sciences in 2022, which expanded its commercial portfolio and strengthened its position in the urologic diagnostics market. The company positions itself as a specialized provider of clinically validated molecular tests integrated into urology workflows and supported by reimbursement relationships with U.S. payors.

Business Operations

MDxHealth generates revenue primarily through the commercialization of molecular diagnostic testing services performed through its laboratory infrastructure and associated reimbursement arrangements with insurers and healthcare providers. Its core operating activities center around the Precision Diagnostics business focused on urologic oncology. Key products include GPS, a genomic assay used to assess prostate cancer aggressiveness; Confirm mdx, an epigenetic assay intended to identify men at risk for undetected prostate cancer following a negative biopsy; Select mdx, a urine-based biomarker test for prostate cancer risk assessment; and Resolve mdx, a molecular urine test intended to support urinary tract infection management.

The company’s commercial operations are concentrated in the United States, which represents the majority of revenue generation, while maintaining corporate roots in Belgium. MDxHealth controls laboratory testing operations, proprietary genomic and epigenetic biomarker technologies, and intellectual property associated with its assays. Strategic relationships with urology groups, healthcare systems, and reimbursement providers support commercialization efforts. The company has also utilized partnerships and licensing arrangements to broaden access to its testing platform and integrate molecular diagnostics into clinical care pathways.

Strategic Position & Investments

MDxHealth’s strategic direction has centered on expanding its prostate cancer diagnostics portfolio, increasing physician adoption, improving reimbursement coverage, and strengthening its position in precision urology. A major strategic development was the acquisition of the Oncotype DX Genomic Prostate Score (GPS) business from Exact Sciences, which significantly expanded MDxHealth’s commercial scale and enhanced its genomic testing capabilities. The company has continued investing in clinical validation studies, payer engagement initiatives, and sales force expansion to increase test utilization across the urology market.

The company has also emphasized evidence generation through peer-reviewed studies and clinical utility programs intended to support broader integration of molecular diagnostics into treatment decision-making. MDxHealth’s strategic focus aligns with broader healthcare trends favoring personalized medicine, minimally invasive testing, and value-based oncology care. Public filings and investor communications indicate ongoing investment in data-driven precision medicine technologies and efforts to improve operating leverage through commercialization efficiencies and expanded reimbursement coverage.

Geographic Footprint

MDxHealth is headquartered in Herstal, Belgium, with significant operational and commercial activities in the United States, including laboratory and corporate functions in California and other U.S. locations. The U.S. market represents the company’s primary commercial focus due to the size of the prostate cancer diagnostics market and reimbursement opportunities through Medicare and private insurers.

While the company maintains a European corporate presence, its commercial footprint is strongest across North America. MDxHealth has historically pursued international opportunities through distributor relationships and physician networks in selected global markets, although public disclosures indicate that the majority of operational influence and revenue generation remains concentrated in the United States. Its international profile is supported by cross-border management, European market access capabilities, and multinational investor participation.

Leadership & Governance

MDxHealth was originally founded in Belgium and has evolved into a publicly traded molecular diagnostics company listed on NASDAQ under the ticker MDXH and on Euronext Brussels. Leadership has focused on expanding the company’s precision oncology platform, improving commercial execution, and building scale within the urology diagnostics sector. Corporate governance is overseen by a board of directors and executive leadership team with backgrounds in diagnostics, biotechnology, healthcare commercialization, and finance.

Key executives include:

• Michael McGarrity – Chief Executive Officer
• Jan Groen – Chairman of the Board
• Dennis O’Donnell – Chief Operating Officer
• Brent Mathews – Chief Financial Officer
• Matthew Gapski – Chief Commercial Officer

Management strategy has emphasized clinical evidence development, reimbursement expansion, disciplined capital allocation, and growth through both internal innovation and acquisitions. Public company disclosures, including SEC filings, investor presentations, and earnings communications, consistently describe a leadership focus on establishing MDxHealth as a leading provider of precision diagnostics for urologic disease management.